1) Vyvanse (lisdexamfetamine) (PG098, Ver
Europace 20 , 12521258 (2018)
Protocol : BPC-157: 500 mcg/day (near injury or systemic) CJC-1295 w/ DAC: 2 mg twice per week Ipamorelin: 100200 mcg, 12x/day Duration: 68 weeks max Stacking Summary Potential Side Effects and Safety Profile of BPC-157 Compared to most performance-enhancing drugs, peptides, or even over-the-counter recovery aids, BPC-157 is remarkably well-tolerated
Oral semaglutide (Rybelsus) requires special consideration, as it must also be taken on an empty stomach and can increase thyroxine exposure when coadministered with levothyroxine, potentially necessitating dose adjustments and careful TSH monitoring
Toast with eggs, a protein shake, or plain yoghurt are all reasonable